Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials

about

Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials

Item

http://www.wikidata.org/entity/Q57495648

description

scientific article published on 06 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Evaluating duration of respons ...... erythematosus clinical trials

@en

Evaluating duration of respons ...... erythematosus clinical trials

@nl

type

Item

label

Evaluating duration of respons ...... erythematosus clinical trials

@en

Evaluating duration of respons ...... erythematosus clinical trials

@nl

prefLabel

Evaluating duration of respons ...... erythematosus clinical trials

@en

Evaluating duration of respons ...... erythematosus clinical trials

@nl

P1476

Evaluating duration of respons ...... erythematosus clinical trials

@en

P2093

Joan T Merrill

http://www.w3.org/2001/XMLSchema#string

Kenneth Kalunian

http://www.w3.org/2001/XMLSchema#string

Leslie Hanrahan

http://www.w3.org/2001/XMLSchema#string

Mimi Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

Impact of standard of care treatments and disease variables on outcomes in systemic lupus erythematosus trials: analysis from the Lupus Foundation of America Collective Data Analysis Initiative

A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach.

Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design.

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controll

Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years.

P304

e000266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/LUPUS-2018-000266

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter Izmirly

P577

2018-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30319781

http://www.w3.org/2001/XMLSchema#string

P932

6088344

http://www.w3.org/2001/XMLSchema#string